Andrew Germain joined Foghorn Therapeutics in 2020 as the head of Intellectual Property. He brings more than 10 years of experience in patent strategy and innovation protection with an educational background in law and chemistry.
Before joining Foghorn, Andrew was a patent attorney at Clark+Elbing, LLP where he advised biotechnology companies with technologies ranging from small molecules to oligonucleotide therapeutics on a wide range of intellectual property matters including, patent strategy, implementing systems to help foster innovation and protect the company’s intellectual property, and assisting in transitions to a public company and business development activities. Prior to his time at Clark+Elbing, LLP, Andrew was an Organic Synthesis Fellow at the Broad Institute where he led teams of medicinal chemists in the development of chemical probes for a wide variety of biologic targets as part of the NIH Molecular Libraries Probe Production Centers Network and in drug development programs for neglected disease targets.
Andrew received his Juris Doctor degree from Suffolk University and his Ph.D. in Chemistry from Boston University, where his research focused on new synthetic methodology development and biomimetic total synthesis of complex natural products.